{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:56Z","timestamp":1783521716780,"version":"3.55.0"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mantle cell lymphoma (MCL) patients can be treated with intensive induction therapy, followed by high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) for consolidation and subsequent anti\u2010CD20 maintenance. For patients relapsing after bruton tyrosine kinase (BTK) inhibitors, CAR T\u2010cell therapy became available in late 2020 fueling the interest in outcomes of relapsing MCL patients. We retrospectively analyzed the outcome of MCL patients receiving HDCT\/ASCT at our center between 2000 and 2021, thus, before availability of CAR\u2010T cells. We identified 97 MCL patients undergoing HDCT\/ASCT in this period with a median follow\u2010up of 52\u00a0months. 43 (44%) patients ultimately relapsed, and 29 (30%) have died. The median progression\u2010free survival (PFS) for the entire cohort was 48\u00a0months and overall survival (OS) was 202\u00a0months. Relapsing patients had a median PFS of only 28\u00a0months and median OS of 105\u00a0months. The OS of relapsing patients receiving BTK inhibitors was 148 versus 78\u00a0months in patients who never received BTK inhibitors (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.1175). Even after HDCT\/ASCT, a substantial proportion of MCL patients will relapse and ultimately die of the disease, emphasizing the need for new therapeutic options including CAR T\u2010cell treatment for this lymphoma subtype.\n                  <\/jats:p>","DOI":"10.1002\/hon.2952","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T05:44:00Z","timestamp":1637732640000},"page":"292-296","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre\u2010CAR T\u2010cell era"],"prefix":"10.1002","volume":"40","author":[{"given":"Anina","family":"Mathys","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital Bern University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, University Hospital Bern University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[{"name":"Institute of Pathology University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Legros","sequence":"additional","affiliation":[{"name":"Center of Laboratory Medicine, Inselspital University Hospital  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Mansouri Taleghani","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, University Hospital Bern University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital Bern University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital Bern University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.006"},{"key":"e_1_2_3_3_1","series-title":"Current treatment standards and emerging strategies in mantle cell lymphoma","first-page":"542","author":"Dreyling M","year":"2009"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2197"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2900-y"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_3_13_1","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves first cell\u2010based gene therapy for adult patients with relapsed or refractory MCL.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010cell\u2010based\u2010gene\u2010therapy\u2010adult\u2010patients\u2010relapsed\u2010or\u2010refractory\u2010mcl. Accessed July 24 2020."},{"key":"e_1_2_3_14_1","unstructured":"European Medicines Agency (EMA)Tecartus (autologous anti\u2010CD19\u2010transduced CD3+ cells): an overview of Tecartus and why it\u00a0is authorised in the EU.https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tecartus\u2010epar\u2010medicine\u2010overview_en.pdfAccessed December 14 2020."},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0783-y"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2952","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:52:25Z","timestamp":1692975145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/hon.2952"],"URL":"https:\/\/doi.org\/10.1002\/hon.2952","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2952\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2952\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2952\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2952\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,5]]},"assertion":[{"value":"2021-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}